Compare AstraZeneca plc (AZN) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Nomura Holdings Inc — how do they compare? AstraZeneca plc trades at $168.14 (market cap $253.13B), while Nomura Holdings Inc trades at $10.05 (market cap $28.06B). The key difference: AstraZeneca plc is far larger — about 9× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| AZN | NMR | |
|---|---|---|
Market Cap | $253.13B | $28.06B |
Sector | Health | Financials |
52-Week High | $209.48 | $9.75 |
52-Week Low | $137.44 | $6.30 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Nomura Holdings (NMR) trades at $9.62, down 0.41% on the day, with a P/E of 13.08 suggesting reasonable valuation. The stock shows bullish technical signals with strong moving average support, though RSI levels indicate overbought conditions. Recent earnings show mixed results with one beat and two misses, but annual revenue grew to $1.66 trillion with a robust 20.49% net margin. The company posted record annual profit of $340.74 billion in 2025, driving positive sentiment around its wholesale and wealth management segments.
Nomura presents a compelling value opportunity with strong profitability metrics and expansion in core businesses, though recent earnings misses and negative operating cash flow pose near-term concerns. The bullish analyst consensus and technical setup support upside potential, but investors should monitor integration costs from recent acquisitions and debt levels that have increased to 26.25% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
